Nkarta, Inc. Common Stock earnings per share and revenue
On Nov 10, 2025, NKTX reported earnings of -0.28 USD per share (EPS) for Q3 25, beating the estimate of -0.31 USD, resulting in a 9.26% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +2.55% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.33 USD, with revenue projected to reach -- USD, implying an increase of 17.86% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were Nkarta, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Nkarta, Inc. Common Stock reported EPS of -$0.28, beating estimates by 9.26%, and revenue of $0.00, 0% as expectations.
How did the market react to Nkarta, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 2.55%, changed from $1.96 before the earnings release to $2.01 the day after.
When is Nkarta, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 12, 2026.
What are the forecasts for Nkarta, Inc. Common Stock's next earnings report?
Based on 6
analysts, Nkarta, Inc. Common Stock is expected to report EPS of -$0.33 and revenue of -- for Q1 2026.